---
schema_version: "secwatch.filing_event.v1"
accession: "0001906324-23-000027"
form_type: "8-K"
ticker: "QDEL"
cik: "0001906324"
company_name: "QuidelOrtho Corp"
filed_at: "2023-04-13T23:59:59+00:00"
generated_at: "2026-06-17T02:49:15.870602+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# QuidelOrtho pre-announces Q1 revenue $840-850M; non-respiratory grows 5-7%

## Summary
- Total preliminary Q1 revenue $840-850M; respiratory $262-267M including COVID-19 $212-217M.
- Non-respiratory revenue $578-583M, up ~5% supplemental combined basis (~7% constant currency).
- Labs business unit drove growth including ~$21M settlement from a collaboration agreement.
- CEO Douglas Bryant says Q1 ahead of expectations; confident in sustainable high-single-digit growth.

## SEC filing metadata
- accession: 0001906324-23-000027
- form_type: 8-K
- ticker: QDEL
- cik: 0001906324
- company_name: QuidelOrtho Corp
- filed_at: 2023-04-13T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1906324/000190632423000027/0001906324-23-000027-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1906324/000190632423000027/qdel-20230413.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001906324-23-000027
- JSON: https://secwatch.observer/filing/0001906324-23-000027.json
- Plain text: https://secwatch.observer/filing/0001906324-23-000027.txt

## Key facts
- Earnings Releases
  QuidelOrtho Corp reported first quarter ended April 2, 2023 results: revenue $840 million to $850 million.
  - Period: first quarter ended April 2, 2023
  - Revenue: $840 million to $850 million
  - Result: preliminary results
  source text: today announced preliminary revenue results for the first quarter ended April 2, 2023. The Company expects total revenues in the first quarter of 2023 to be in the range of $840 million to $850 million. Respiratory product revenue is expected to be in the range of $262 million to $267 million, including COVID-19 product revenue of $212 million to $217 million.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1906324/000190632423000027/0001906324-23-000027-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.